(Updates with closing price starting in first paragraph.)
Jan. 25 (Bloomberg) -- Medigus Ltd. surged the most since August 2009 after the company said it will seek U.S. Food and Drug Administration approval to market its SRS device for the treatment of gastro-esophageal reflux disease.
The shares of the devloper of endoscopic procedures and devices rose 22 percent, the most since Aug. 3, 2009, to 0.734 shekel at the 4:30 p.m. close in Tel Aviv.
--With assistance from Gwen Ackerman in Jerusalem. Editors: Daliah Merzaban, Susan Lerner
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org